文献速递前列腺癌

OLIGOPELVIS 2-GETUG P12研究方案:间歇性雄激素剥夺治疗联合或不联合挽救性高剂量调强放疗治疗前列腺癌寡复发盆腔及腹主动脉旁淋巴结的随机3期研究

Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-06-12

OLIGOPELVIS 2-GETUG P12是一项多中心随机3期试验,纳入1-5个寡复发盆腔和/或腹主动脉旁淋巴结的前列腺癌患者,随机接受6个月间歇性雄激素剥夺治疗(IADT)单用或联合挽救性盆腔图像引导调强放疗(IG-IMRT,盆腔54 Gy/30次,淋巴结66 Gy/30次)。主要终点为无进展生存期,计划入组256例患者。该研究旨在评估联合放疗能否延长首次失败至第二次IADT之间的无失败间期,同时保持可接受的毒性和生活质量。

要点

  • 针对前列腺癌寡复发盆腔/腹主动脉旁淋巴结(1-5个)患者。
  • 随机比较6个月IADT单用 vs. IADT联合挽救性盆腔IG-IMRT。
  • 主要终点为无进展生存期,计划样本量256例。

核心结论

  • 该3期试验将探索挽救性盆腔IG-IMRT联合IADT在寡复发盆腔淋巴结前列腺癌中延长首次与第二次IADT之间无失败间期的价值。

研究设计与样本

  • 多中心随机3期试验,随机分配患者至A组(IADT单用6个月)或B组(挽救性盆腔IG-IMRT联合IADT)。
  • 计划纳入256例前列腺癌患者,要求1-5个寡复发盆腔和/或腹主动脉旁淋巴结。
  • 放疗剂量:盆腔54 Gy/30次,淋巴结66 Gy/30次。

主要发现

  • 原文未报告研究结果。

关键数值与推荐

  • 主要终点无进展生存期定义为从随机化至生化-临床失败或任何原因死亡的时间。
  • 入组标准:1-5个寡复发盆腔和/或腹主动脉旁淋巴结。
  • 干预:A组IADT 6个月;B组IADT联合盆腔IG-IMRT(54 Gy/30次)和淋巴结放疗(66 Gy/30次)。

临床怎么用

  • 对于前列腺癌寡复发盆腔/腹主动脉旁淋巴结患者,可考虑在6个月IADT基础上联合挽救性盆腔IG-IMRT以延长无失败间期。

局限性

  • 研究为开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of oligorecurrent pelvic lymph nodes in patients with prostate cancer is debated. Intermittent androgen-deprivation therapy (ADT; IADT) is often proposed. Elective pelvis irradiation (ENRT) may prolong tumor control and decrease subsequent spread. OBJECTIVE: To assess the efficacy of a combination of 6 mo of IADT with or without ENRT to treat patients with oligorecurrent pelvic and para-aortic lymph nodes of prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: The OLIGOPELVIS 2-GETUG P12 trial is a multicenter randomized phase 3 trial, randomizing patients with 1-5 oligorecurrent pelvic and/or para-aortic lymph nodes of prostate cancer between arm A (IADT alone for 6 mo) versus arm B (salvage pelvic image-guided intensity-modulated radiotherapy [IG-IMRT], 54 Gy, 30 fractions to the pelvis and 66 Gy, 30 fractions to the lymph nodes) combined with IADT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome is progression-free survival, defined as the time from randomization until a biochemical-clinical failure is detected or death from any cause. In total, 256 patients will be included. RESULTS AND LIMITATIONS: In this population of patients requiring ADT, ENRT may demonstrate antitumoral efficacy while achieving acceptable toxicity and maintaining quality of life. Limitations are mainly inherent to the open-label design of this study. CONCLUSIONS: This phase 3 study will explore the role of salvage pelvic IG-IMRT combined with IADT in patients with oligorecurrent pelvic lymph nodes of prostate cancer in prolonging the first failure-free interval between the first and the second IADT courses. PATIENT SUMMARY: The OLIGOPELVIS 2-GETUG P12 clinical trial assesses short-term (6 mo) androgen-deprivation therapy in association with external beam radiation therapy in men with prostate cancer relapsing to pelvic and para-aortic lymph nodes of prostate cancer. The trial investigates whether radiotherapy targeting pelvic and para-aortic lymph nodes can improve the biological response while maintaining a favorable tolerability profile. TRIAL REGISTRATION: NCT03630666, RCB 2018-A00551-54, date of registration: 2018-12-04.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Josset Q, Blanc-Lapierre A, Pigne G, et al. Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer. Eur Urol Oncol. 2026. PMID: 42276876. doi:10.1016/j.euo.2026.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。